Robeco Institutional Asset Management B.V. Raises Stake in Royalty Pharma PLC $RPRX

Robeco Institutional Asset Management B.V. raised its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 61.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,248,619 shares of the biopharmaceutical company’s stock after purchasing an additional 474,459 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Royalty Pharma were worth $44,051,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in RPRX. Royal Bank of Canada increased its position in Royalty Pharma by 367.7% in the 1st quarter. Royal Bank of Canada now owns 203,760 shares of the biopharmaceutical company’s stock valued at $6,342,000 after acquiring an additional 160,191 shares during the period. EP Wealth Advisors LLC purchased a new position in shares of Royalty Pharma in the 1st quarter valued at approximately $242,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Royalty Pharma by 20.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,990 shares of the biopharmaceutical company’s stock valued at $2,490,000 after purchasing an additional 13,489 shares during the period. Petrus Trust Company LTA acquired a new position in shares of Royalty Pharma in the first quarter valued at approximately $227,000. Finally, Empowered Funds LLC purchased a new stake in shares of Royalty Pharma during the first quarter worth approximately $8,013,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RPRX. TD Cowen lifted their price objective on shares of Royalty Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 28th. Weiss Ratings cut shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. Finally, Leerink Partners set a $45.00 price objective on Royalty Pharma in a report on Thursday, December 11th. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Royalty Pharma presently has an average rating of “Moderate Buy” and an average target price of $45.60.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $41.39 on Thursday. The company has a current ratio of 3.48, a quick ratio of 3.48 and a debt-to-equity ratio of 0.89. The stock has a market cap of $23.89 billion, a price-to-earnings ratio of 31.36, a PEG ratio of 1.95 and a beta of 0.43. The company’s 50-day moving average price is $39.07 and its 200 day moving average price is $37.22. Royalty Pharma PLC has a 52 week low of $25.76 and a 52 week high of $41.41.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The business had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. As a group, research analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Friday, November 14th. Royalty Pharma’s dividend payout ratio is currently 66.67%.

Insider Activity at Royalty Pharma

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $39.32, for a total transaction of $786,400.00. Following the sale, the executive vice president directly owned 100,000 shares of the company’s stock, valued at $3,932,000. This trade represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George W. Lloyd sold 30,654 shares of Royalty Pharma stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $38.50, for a total transaction of $1,180,179.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 846,511 shares of company stock valued at $33,011,004 over the last quarter. Insiders own 18.90% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.